Liver-dominant ocular melanoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Although eye cancers are generally rare, ocular melanoma is the most common type. Even more amazing is the fact that 95% of people with this type of cancer have liver involvement as the first organ affected by the eye cancer cells. About 50% of people with this type of cancer go on to develop metastatic disease. 5 to 13% of all melanomas are primary ocular. The most common primary intraocular tumor in adults is ocular melanoma, which accounts for about 60% of all noncutaneous melanoma lesions. Ocular melanoma is the most common type of cancer of the adult eye. About 50% of patients with ocular melanoma progress to develop metastatic disease. Once OM has spread past the eye, it is regarded as metastatic.

Description

Though it is a rare cancer, ocular melanoma is the most common type of eye cancer. Even more astonishing is the fact that the liver is the first organ to be affected by eye cancer cells in 95% of cases, and that approximately 50% of those who are diagnosed with this type of cancer go on to develop metastatic disease. Melanoma does not spread via the lymphatic system like other cancers; instead, it does so via the circulatory system. The liver's job is to clean the blood, so when ocular melanoma patients have secondary tumors, the liver absorbs cancer cells as it functions. Once the cancer has spread or metastatic, the prognosis for patients with ocular melanoma is typically poor. According to the Ocular Melanoma Foundation, the median survival time after metastasis is 2-8 months without treatment.

Liver-dominant ocular melanoma (Epidemiology)

Between 5 and 13% of all melanomas are primary ocular. Ocular melanoma is the most frequent primary intraocular tumor in adults, accounting for about 60% of all noncutaneous melanoma lesions. After five years, the mortality rate is 25%, with death being a frequent outcome. As opposed to 0.31 in the Black, 0.38 in the Asian, and 1.67 in the Hispanic populations, the incidence of ocular melanoma was 6.02 per million in the US white population. People with light pigmentation are much more likely to develop ocular melanoma. Skin cancer incidence in Caucasians ranges from 0.49 to 0.76 per 100,000, with a rate of 5-77 per 100,000 per year. After age 65, the incidence rises to 2 points per 100,000 per year. 400 to 500 Germans and approximately 1,500 Americans are affected by this cancer each year.

Liver-dominant ocular melanoma -Current Market Size & Forecast Trends

The market for liver-dominant ocular melanoma, specifically uveal melanoma with liver metastases, is projected to grow significantly, with the uveal melanoma treatment market expected to reach approximately USD 1.6 billion by 2035, up from USD 1 billion in 2024, reflecting a compound annual growth rate (CAGR) of 4.28% during the forecast period from 2025 to 2035. Uveal melanoma is the most common intraocular malignant tumor in adults, and while local control treatments are effective, about 50% of patients develop distant metastases, predominantly to the liver. The increasing incidence of liver metastases from uveal melanoma, combined with advancements in treatment options such as targeted therapies and immunotherapies, is expected to drive market growth. Additionally, ongoing research and clinical trials aimed at improving patient outcomes will further enhance the market landscape through 2035. Overall, the liver-dominant ocular melanoma market is well-positioned for substantial expansion as new therapeutic strategies emerge to address this challenging condition.

Ocular melanoma is the most common adult eye cancer. About 50% of patients with ocular melanoma progress to develop metastatic disease. When OM has spread outside the eye, it is referred to as metastatic. The liver is the site of metastasis for OM in almost 90% of cases. The prognosis is typically poor once the tumor has spread. 2 to 8 months is the range for the median survival time without treatment. Because it spreads through the bloodstream rather than the lymphatic system, ocular melanoma can metastasize to the liver. Despite the fact that there are currently no approved treatments for metastatic OM, there are numerous palliative therapies and fresh clinical trials available in the US and Europe. In contrast to the generally ineffectiveness of conventional chemotherapy, a novel experimental therapy known as percutaneous hepatic perfusion (PHP) shows promise. Clinical trials are currently being managed by the National Cancer Institute. PHP involves isolating the liver and injecting it with the chemotherapy drug Melphalan. Throughout the procedure, numerous skin punctures with needles are made, and a catheter with balloons on either end is inserted. The balloons are inflated and then seal off the vein above and below the liver. High-dose chemotherapy is heated, isolated, and infused through the liver. Once the blood has been through charcoal filters to remove the chemotherapy, it is returned to the body through a second catheter in the neck.

Report Highlights

Liver-dominant ocular melanoma - Current Market Trends

Liver-dominant ocular melanoma - Current & Forecasted Cases across the G8 Countries

Liver-dominant ocular melanoma - Market Opportunities and Sales Potential for Agents

Liver-dominant ocular melanoma - Patient-based Market Forecast to 2035

Liver-dominant ocular melanoma - Untapped Business Opportunities

Liver-dominant ocular melanoma - Product Positioning Vis-a-vis Competitors' Products

Liver-dominant ocular melanoma - KOLs Insight